Herein, we show that the ability of cisplatin or taxol to induce senescence in ovarian cancer cells depends on tumor genotype, being substantially more pronounced following treatment of Brca1-deficient (compared to Brca1-proficient) ovarian tumors. This evidence concerns the gene BRCA1 and neoplasm.